A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression - Join Clinical Trial NCTNCT06365853
How to Join This Clinical Trial - NCTNCT06365853
Learn how to participate in this PHASE2 trial studying an investigational therapy for Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Toxic Optic Neuropathy, Recurrence. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Toxic Optic Neuropathy, Recurrence. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Toxic Optic Neuropathy, Recurrence
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE2 - Safety and effectiveness study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT06365853 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 40 locations. Find a study site near you:
Clinical Research Site
Los Angeles, California 90095 - United States
Status: RECRUITING
Clinical Research Site
Louisville, Kentucky 40207 - United States
Status: COMPLETED
Clinical Research Site
Silver Spring, Maryland 20910 - United States
Status: RECRUITING
Clinical Research Site
Saint Louis, Missouri 63141 - United States
Status: RECRUITING
Clinical Research Site
Reno, Nevada 89511 - United States
Status: ACTIVE_NOT_RECRUITING
Clinical Research Site
Teaneck, New Jersey 07666 - United States
Status: RECRUITING
Clinical Research Site
Albany, New York 12206-5013 - United States
Status: COMPLETED
Clinical Research Site
Albany, New York 12208 - United States
Status: COMPLETED
Clinical Research Site
Durham, North Carolina 27710 - United States
Status: RECRUITING
Clinical Research Site
Akron, Ohio 44304-1407 - United States
Status: RECRUITING
And 30 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE2 clinical trial for Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Toxic Optic Neuropathy, Recurrence:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships